Ardent Health, Inc. ARDT
10.54
0.06
0.57%
as of 25 Sep
- Market cap
- $1.5B
- P/E
- 19.2×
Follow ARDT
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
17.89 | 9.01 | 9.10 | 9.01 |
+8 more quarters Free account |
P/S ratio |
0.22 | 0.19 | 0.20 | 0.30 | |
P/FCF ratio |
4.57 | 5.55 | 4.81 | 11.88 | |
P/Operating CF |
7.09 | (20.08) | 5.56 | 12.12 | |
P/B ratio |
0.80 | 0.70 | 0.74 | 1.15 | |
Price to Tangible BV |
1.79 | 1.58 | 1.73 | 2.81 | |
EV/Sales |
0.28 | 0.27 | 0.26 | 0.37 | |
EV/EBITDA |
4.16 | 3.38 | 3.36 | 4.42 | |
EV/Operating CF |
3.44 | 3.93 | 3.47 | 6.46 | |
EV/FCF |
5.81 | 7.84 | 6.31 | 15.04 | |
Quick Ratio |
1.45 | 1.36 | 1.33 | 1.42 | |
Current Ratio |
2.10 | 2.12 | 1.97 | 2.08 | |
Net Debt/EBITDA |
3.85 | 4.02 | 2.66 | 8.76 | |
Debt/Assets |
20.87% | 21.14% | 20.78% | 21.46% | |
Debt/Equity |
0.63 | 0.64 | 0.65 | 0.68 | |
Asset Turnover |
1.24 | 1.27 | 1.23 | 1.27 | |
Operating CF/Net income |
11.64 | (1.51) | 4.97 | (6.58) | |
Capex/Depreciation |
(0.92) | (0.64) | (2.01) | (1.46) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
79.13% | 77.85% | 77.17% | 79.78% | |
Intangible Assets out of Total Assets |
0.18 | 0.18 | 0.18 | 0.19 | |
Share Based Compensation of Revenue |
0.49% | 0.56% | 0.57% | 0.61% | |
Graham Net Nets |
(1.06) | (1.24) | (1.24) | (0.84) | |
Graham Number |
12.35 | 16.20 | 16.17 | 19.56 | |
Earnings Yield |
5.59% | 11.10% | 10.99% | 11.09% | |
Free Cash Flow Yield |
21.86% | 18.03% | 20.81% | 8.41% | |
Revenue per Share |
11.45 | 11.34 | 11.40 | 11.16 | |
Operating CF per Share |
1.39 | (0.43) | 1.59 | 1.09 | |
Capex per Share |
(0.27) | (0.20) | (0.60) | (0.42) | |
Free Cash Flow per Share |
1.12 | (0.63) | 0.99 | 0.68 | |
Cash per Share |
5.11 | 4.32 | 5.04 | 4.32 | |
Shareholders Equity per Share |
12.32 | 12.28 | 11.98 | 11.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.32 | 12.28 | 11.98 | 11.57 | |
Free Cash Flow |
158.06 | (88.31) | 139.44 | 95.57 | |
Working Capital |
1,078.55 | 1,068.66 | 1,012.28 | 1,014.31 | |
Capital Expenditures |
(38.68) | (28.09) | (83.99) | (58.80) | |
Net Current Asset Value |
(1,479.14) | (1,497.70) | (1,545.17) | (1,563.58) | |
EV/EBIT |
6.87 | 5.04 | 5.01 | 6.26 | |
Capex to Sales |
0.02 | 0.02 | 0.05 | 0.04 | |
Net Profit Margin |
1.04% | 2.49% | 2.80% | (1.49%) | |
Price to Operating Income |
5.41 | 3.56 | 3.82 | 4.95 | |
| Other line items | |||||
Average Receivables |
727.30 | 731.25 | 714.57 | 717.58 | |
Average Payables |
397.11 | 395.82 | 429.59 | 375.35 | |
Average Inventory |
117.21 | 120.10 | 116.84 | 114.91 | |
Average Assets |
5,153.67 | 5,082.04 | 5,123.15 | 4,977.19 | |
Average Common Equity |
1,697.09 | 1,649.82 | 1,603.71 | 1,508.91 |
Columns are period end dates